Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system

Thrombosis Research

Volumn 135, Issue 4, 2015, Pages 770-773

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Fukami, Kei ^a   Ueda, Seiji ^a   Okuda, Seiya ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 2; REACTIVE OXYGEN METABOLITE; RIVAROXABAN; THROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

CELL ADHESION; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; GENE EXPRESSION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; KIDNEY INJURY; KIDNEY TUBULE CELL; LETTER; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; UPREGULATION; METABOLISM;

FACTOR XA INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; OXIDATIVE STRESS; RECEPTOR, PAR-2; RIVAROXABAN; THROMBIN;

EID: 84925016229     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.01.023     Document Type: Letter

References (17)

1. S. Yamagishi, and T. Matsui Advanced glycation end products, oxidative stress and diabetic nephropathy Oxid Med Cell Longev 3 2010 101 108
2. J.M. Forbes, and M.E. Cooper Glycation in diabetic nephropathy Amino Acids 42 2012 1185 1192
3. M. Daroux, G. Prévost, H. Maillard-Lefebvre, C. Gaxatte, V.D. D'Agati, and A.M. Schmidt Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies Diabetes Metab 36 2010 1 10
4. T. Kato, T. Yamashita, A. Sekiguchi, T. Tsuneda, K. Sagara, and M. Takamura AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat J Cardiovasc Electrophysiol 19 2008 415 420
5. S. Raposeiras-Roubín, B.K. Rodiño-Janeiro, L. Grigorian-Shamagian, A. Seoane-Blanco, M. Moure-González, and A. Varela-Román Evidence for a role of advanced glycation end products in atrial fibrillation Int J Cardiol 157 2012 397 402
6. O. Fatemi, E. Yuriditsky, C. Tsioufis, D. Tsachris, T. Morgan, and J. Basile Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study) Am J Cardiol 114 2014 1217 1222
7. H. Reinecke, M. Nabauer, A. Gerth, T. Limbourg, A. Treszl, and C. Engelbertz Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease Kidney Int 2014 10.1038/ki.2014.195
8. D. Tsiachris, C. Tsioufis, P. Mazzone, N. Katsiki, and C. Stefanadis Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad Curr Vasc Pharmacol 2014 10.2174/1570161112666140519154615
9. J.L. Taft, C.J. Nolan, S.P. Yeung, T.D. Hewitson, and F.I. Martin Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria Diabetes 43 1994 1046 1051
10. F.N. Ziyadeh, and S. Goldfarb The renal tubulointerstitium in diabetes mellitus Kidney Int 39 1991 464 475
11. Y. Ishibashi, T. Matsui, S. Ueda, K. Fukami, and S. Yamagishi Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression Cardiovasc Diabetol 13 2014 60
12. A. Ojima, Y. Ishibashi, T. Matsui, S. Maeda, Y. Nishino, and M. Takeuchi Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression Am J Pathol 182 2013 132 141
13. T. Morii, H. Fujita, T. Narita, T. Shimotomai, H. Fujishima, and N. Yoshioka Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy J Diabetes Complications 17 2003 11 15
14. F.Y. Chow, D.J. Nikolic-Paterson, F.Y. Ma, E. Ozols, B.J. Rollins, and G.H. Tesch Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice Diabetologia 50 2007 471 480
15. D.A. Vesey, C.W. Cheung, W.A. Kruger, P. Poronnik, G. Gobe, and D.W. Johnson Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells Kidney Int 67 2005 1315 1329
16. G. Grandaliano, P. Pontrelli, G. Cerullo, R. Monno, E. Ranieri, and M. Ursi Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis J Am Soc Nephrol 14 2003 2072 2083
17. D. Kubitza, M. Becka, A. Roth, and W. Mueck The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban, an oral, direct Factor Xa inhibitor J Clin Pharmacol 53 2013 249 255